{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T12:16:46Z","timestamp":1793881006004,"version":"4.7.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T00:00:00Z","timestamp":1606953600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Convention Industrielle de Formation par la REcherche"},{"name":"Agence Nationale pour la Recherche sur le SIDA et les hepatites virales","award":["ECTZ8323"],"award-info":[{"award-number":["ECTZ8323"]}]},{"name":"Agence Nationale pour la Recherche sur le SIDA et les hepatites virales","award":["ECTZ8323"],"award-info":[{"award-number":["ECTZ8323"]}]},{"name":"Agence Nationale pour la Recherche sur le SIDA et les hepatites virales","award":["ECTZ8323"],"award-info":[{"award-number":["ECTZ8323"]}]},{"name":"Evotec","award":["Sanofi-Aviesan collaboration"],"award-info":[{"award-number":["Sanofi-Aviesan collaboration"]}]},{"name":"Evotec","award":["Sanofi-Aviesan collaboration"],"award-info":[{"award-number":["Sanofi-Aviesan collaboration"]}]},{"name":"Evotec","award":["Sanofi-Aviesan collaboration"],"award-info":[{"award-number":["Sanofi-Aviesan collaboration"]}]},{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Hepatitis B virus (HBV) covalently closed circular (ccc)DNA is the key genomic form responsible for viral persistence and virological relapse after treatment withdrawal. The assessment of residual intrahepatic cccDNA levels and activity after long-term nucleos(t)ide analogues therapy still represents a technical challenge. Quantitative (q)PCR, rolling circle amplification (RCA) and droplet digital (dd)PCR assays were used to quantify residual intrahepatic cccDNA in liver biopsies from 56 chronically HBV infected patients after 3 to 5\u00a0years of telbivudine treatment. Activity of residual cccDNA was evaluated by quantifying 3.5 kB HBV RNA (preC\/pgRNA) and by assessing cccDNA-associated histone tails post-transcriptional modifications (PTMs) by micro-chromatin immunoprecipitation. Long-term telbivudine treatment resulted in serum HBV DNA suppression, with most of the patients reaching undetectable levels. Despite 38 out of 56 patients had undetectable cccDNA when assessed by qPCR, RCA and ddPCR assays detected cccDNA in all-but-one negative samples. Low preC\/pgRNA level in telbivudine-treated samples was associated with enrichment for cccDNA histone PTMs related to\u00a0repressed transcription. No difference in cccDNA levels was found according to serum viral markers evolution. This panel of cccDNA evaluation techniques should provide an added value for the new proof-of-concept clinical trials aiming at a functional cure of chronic hepatitis B.<\/jats:p>","DOI":"10.1038\/s41598-020-78001-1","type":"journal-article","created":{"date-parts":[[2020,12,3]],"date-time":"2020-12-03T11:02:35Z","timestamp":1606993355000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Quantification and epigenetic evaluation of the residual pool of hepatitis B covalently closed circular DNA in long-term nucleoside analogue-treated patients"],"prefix":"10.1038","volume":"10","author":[{"given":"Fanny","family":"Leboss\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurore","family":"Inchausp\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00eblle","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clothilde","family":"Miaglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Diederichs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Fresquet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fleur","family":"Chapus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamal","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Testoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,12,3]]},"reference":[{"key":"78001_CR1","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","volume":"8","author":"C de Martel","year":"2020","unstructured":"de Martel, C., Georges, D., Bray, F., Ferlay, J. & Clifford, G. M. Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. Lancet Glob. Health 8, e180\u2013e190 (2020).","journal-title":"Lancet Glob. Health"},{"key":"78001_CR2","unstructured":"WHO Fact Sheets https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b"},{"key":"78001_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-309809","author":"M Nassal","year":"2015","unstructured":"Nassal, M. HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut https:\/\/doi.org\/10.1136\/gutjnl-2015-309809 (2015).","journal-title":"Gut"},{"key":"78001_CR4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jhep.2004.12.015","volume":"42","author":"F Zoulim","year":"2005","unstructured":"Zoulim, F. New insight on hepatitis B virus persistence from the study of intrahepatic viral cccDNA. J. Hepatol. 42, 302\u2013308 (2005).","journal-title":"J. Hepatol."},{"key":"78001_CR5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","volume":"51","author":"M Levrero","year":"2009","unstructured":"Levrero, M. et al. Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 51, 581\u2013592 (2009).","journal-title":"J. Hepatol."},{"key":"78001_CR6","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1038\/nm1096-1104","volume":"2","author":"B Rehermann","year":"1996","unstructured":"Rehermann, B., Ferrari, C., Pasquinelli, C. & Chisari, F. V. The hepatitis B virus persists for decades after patients\u2019 recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat. Med. 2, 1104\u20131108 (1996).","journal-title":"Nat. Med."},{"key":"78001_CR7","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1002\/hep.29479","volume":"66","author":"X Hong","year":"2017","unstructured":"Hong, X., Kim, E. S. & Guo, H. Epigenetic regulation of hepatitis B virus covalently closed circular DNA: Implications for epigenetic therapy against chronic hepatitis B. Hepatol. Baltim. Md 66, 2066\u20132077 (2017).","journal-title":"Hepatol. Baltim. Md"},{"key":"78001_CR8","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1053\/j.gastro.2006.01.001","volume":"130","author":"T Pollicino","year":"2006","unstructured":"Pollicino, T. et al. Hepatitis B virus replication is regulated by the acetylation status of hepatitis B virus cccDNA-bound H3 and H4 histones. Gastroenterology 130, 823\u2013837 (2006).","journal-title":"Gastroenterology"},{"key":"78001_CR9","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1002\/hep.29912","volume":"68","author":"J-H Ren","year":"2018","unstructured":"Ren, J.-H. et al. SIRT3 restricts hepatitis B virus transcription and replication through epigenetic regulation of covalently closed circular DNA involving suppressor of variegation 3\u20139 homolog 1 and SET domain containing 1A histone methyltransferases. Hepatol. Baltim. Md 68, 1260\u20131276 (2018).","journal-title":"Hepatol. Baltim. Md"},{"key":"78001_CR10","doi-asserted-by":"crossref","unstructured":"Flecken, T. et al. Mapping the heterogeneity of histone modifications on hepatitis B virus DNA using liver needle biopsies obtained from chronically infected patients. J. Virol. 93 (2019).","DOI":"10.1128\/JVI.02036-18"},{"key":"78001_CR11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1136\/gutjnl-2016-312162","volume":"67","author":"L Allweiss","year":"2018","unstructured":"Allweiss, L. et al. Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. Gut 67, 542\u2013552 (2018).","journal-title":"Gut"},{"key":"78001_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308943","author":"MB Zeisel","year":"2015","unstructured":"Zeisel, M. B. et al. Towards an HBV cure: State-of-the-art and unresolved questions-report of the ANRS workshop on HBV cure. Gut https:\/\/doi.org\/10.1136\/gutjnl-2014-308943 (2015).","journal-title":"Gut"},{"key":"78001_CR13","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.jhep.2016.05.014","volume":"65","author":"A Boyd","year":"2016","unstructured":"Boyd, A. et al. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. J. Hepatol. 65, 683\u2013691 (2016).","journal-title":"J. Hepatol."},{"key":"78001_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.08.022","author":"C-L Lai","year":"2016","unstructured":"Lai, C.-L. et al. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2016.08.022 (2016).","journal-title":"J. Hepatol."},{"key":"78001_CR15","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2468-1253(19)30119-0","volume":"4","author":"PA Revill","year":"2019","unstructured":"Revill, P. A. et al. A global scientific strategy to cure hepatitis B. Lancet Gastroenterol. Hepatol. 4, 545\u2013558 (2019).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"78001_CR16","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu & European Association for the Study of the Liver. EASL 2017 Clinical practice guidelines on the management of hepatitis B virus infection. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.021 (2017).","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"78001_CR17","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1053\/j.gastro.2004.03.018","volume":"126","author":"B Werle-Lapostolle","year":"2004","unstructured":"Werle-Lapostolle, B. et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 126, 1750\u20131758 (2004).","journal-title":"Gastroenterology"},{"key":"78001_CR18","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1007\/s10529-015-1890-5","volume":"37","author":"D Mu","year":"2015","unstructured":"Mu, D., Yan, L., Tang, H. & Liao, Y. A sensitive and accurate quantification method for the detection of hepatitis B virus covalently closed circular DNA by the application of a droplet digital polymerase chain reaction amplification system. Biotechnol. Lett. 37, 2063\u20132073 (2015).","journal-title":"Biotechnol. Lett."},{"key":"78001_CR19","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1038\/s41598-017-05242-y","volume":"7","author":"D Mu","year":"2017","unstructured":"Mu, D. et al. Baseline value of intrahepatic HBV DNA over cccDNA predicts patient\u2019s response to interferon therapy. Sci. Rep. 7, 5937 (2017).","journal-title":"Sci. Rep."},{"key":"78001_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.03.021","author":"GP Caviglia","year":"2018","unstructured":"Caviglia, G. P. et al. Quantitation of HBV cccDNA in anti-HBc-positive liver donors by droplet digital PCR: A new tool to detect occult infection. J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.021 (2018).","journal-title":"J. Hepatol."},{"key":"78001_CR21","doi-asserted-by":"publisher","first-page":"E5715","DOI":"10.1073\/pnas.1518090112","volume":"112","author":"P Tropberger","year":"2015","unstructured":"Tropberger, P. et al. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. Proc. Natl. Acad. Sci. U. S. A. 112, E5715-5724 (2015).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"78001_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/liv.13307","volume":"37","author":"B Testoni","year":"2017","unstructured":"Testoni, B., Durantel, D. & Zoulim, F. Novel targets for hepatitis B virus therapy. Liver Int. 37, 33\u201339 (2017).","journal-title":"Liver Int."},{"key":"78001_CR23","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1053\/j.gastro.2007.06.057","volume":"133","author":"T Volz","year":"2007","unstructured":"Volz, T. et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology 133, 843\u2013852 (2007).","journal-title":"Gastroenterology"},{"key":"78001_CR24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","volume":"66","author":"F Leboss\u00e9","year":"2017","unstructured":"Leboss\u00e9, F. et al. Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. J. Hepatol. 66, 897\u2013909 (2017).","journal-title":"J. Hepatol."},{"key":"78001_CR25","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.jhep.2018.11.030","volume":"70","author":"B Testoni","year":"2019","unstructured":"Testoni, B. et al. Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. J. Hepatol. 70, 615\u2013625 (2019).","journal-title":"J. Hepatol."},{"key":"78001_CR26","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/gutjnl-2014-309011","volume":"65","author":"B Testoni","year":"2016","unstructured":"Testoni, B. et al. Ribavirin restores IFN\u03b1 responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. Gut 65, 672\u2013682 (2016).","journal-title":"Gut"},{"key":"78001_CR27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/carcin\/bgt317","volume":"35","author":"Y Tian","year":"2014","unstructured":"Tian, Y. et al. Telbivudine treatment corrects HBV-induced epigenetic alterations in liver cells of patients with chronic hepatitis B. Carcinogenesis 35, 53\u201361 (2014).","journal-title":"Carcinogenesis"},{"key":"78001_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.canlet.2017.02.003","volume":"392","author":"S Zhang","year":"2017","unstructured":"Zhang, S. et al. Anti-HBV drugs suppress the growth of HBV-related hepatoma cells via down-regulation of hepatitis B virus X protein. Cancer Lett. 392, 94\u2013104 (2017).","journal-title":"Cancer Lett."},{"key":"78001_CR29","doi-asserted-by":"publisher","first-page":"19975","DOI":"10.1073\/pnas.0908365106","volume":"106","author":"L Belloni","year":"2009","unstructured":"Belloni, L. et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc. Natl. Acad. Sci. U. S. A. 106, 19975\u201319979 (2009).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"78001_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz607","author":"A Balagopal","year":"2019","unstructured":"Balagopal, A. et al. Single hepatocyte hepatitis B virus transcriptional landscape in HIV co-infection. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiz607 (2019).","journal-title":"J. Infect. Dis."},{"key":"78001_CR31","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/hep.22075","volume":"47","author":"J Hou","year":"2008","unstructured":"Hou, J. et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatol. Baltim. Md 47, 447\u2013454 (2008).","journal-title":"Hepatol. Baltim. Md"},{"key":"78001_CR32","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s12325-015-0232-2","volume":"32","author":"J-L Hou","year":"2015","unstructured":"Hou, J.-L. et al. Long-term telbivudine treatment results in resolution of liver inflammation and fibrosis in patients with chronic hepatitis B. Adv. Ther. 32, 727\u2013741 (2015).","journal-title":"Adv. Ther."},{"key":"78001_CR33","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1056\/NEJMoa066422","volume":"357","author":"C-L Lai","year":"2007","unstructured":"Lai, C.-L. et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357, 2576\u20132588 (2007).","journal-title":"N. Engl. J. Med."},{"key":"78001_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jhep.2008.12.019","volume":"51","author":"S Zeuzem","year":"2009","unstructured":"Zeuzem, S. et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J. Hepatol. 51, 11\u201320 (2009).","journal-title":"J. Hepatol."},{"key":"78001_CR35","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1128\/AAC.01318-07","volume":"52","author":"S Margeridon","year":"2008","unstructured":"Margeridon, S. et al. Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA. Antimicrob. Agents Chemother. 52, 3068\u20133073 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"78001_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1016\/j.jviromet.2013.07.045","volume":"193","author":"N Martel","year":"2013","unstructured":"Martel, N., Gomes, S. A., Chemin, I., Tr\u00e9po, C. & Kay, A. Improved rolling circle amplification (RCA) of hepatitis B virus (HBV) relaxed-circular serum DNA (RC-DNA). J. Virol. Methods 193, 653\u2013659 (2013).","journal-title":"J. Virol. Methods"},{"key":"78001_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.antiviral.2017.07.006","volume":"145","author":"J Lucifora","year":"2017","unstructured":"Lucifora, J. et al. Detection of the hepatitis B virus (HBV) covalently-closed-circular DNA (cccDNA) in mice transduced with a recombinant AAV-HBV vector. Antiviral Res. 145, 14\u201319 (2017).","journal-title":"Antiviral Res."},{"key":"78001_CR38","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1128\/JVI.69.9.5437-5444.1995","volume":"69","author":"S G\u00fcnther","year":"1995","unstructured":"G\u00fcnther, S. et al. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J. Virol. 69, 5437\u20135444 (1995).","journal-title":"J. Virol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78001-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78001-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T00:24:27Z","timestamp":1670372667000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-78001-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,3]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["78001"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-78001-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,3]]},"assertion":[{"value":"2 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"FL, AI, ML, CM, AD, JF, FC declare no conflicts of interest. KH was a formerly Novartis employee. FZ and BT received grants from Evotec, Hoffmann-La Roche and Novartis.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21097"}}